FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2786284951> ?p ?o ?g. }

• W2786284951 endingPage "985" @default.
• W2786284951 startingPage "976" @default.
• W2786284951 abstract "Several recent clinical trials have successfully incorporated a costimulatory domain derived from either CD28 or 4-1BB with the original CD3ζ T cell activating domain to form second-generation chimeric antigen receptors (CARs) that can increase the responsiveness and survival of CAR-engineered T (CAR-T) cells. However, a rigorous assessment of the individual benefits of these costimulatory components relative to the in vivo performance of infused T cells in patients is still lacking. Therefore, we have designed a study that allows us to investigate and compare the impact of different costimulatory signal domains on CAR-T cells in vivo. Patients with B cell leukemia were infused with a mixture of two types of CD19-specific CAR-T cells, individually bearing CD28 (28ζ) and 4-1BB (BBζ) costimulatory signaling domains. We found that such a clinical procedure was feasible and safe. Complete remission (CR) was observed in five of seven enrolled patients, with two patients exhibiting durable CR lasting more than 15 months. The in vivo expansion pattern of 28ζ and BBζ CAR-T cells varied significantly among individual patients. These results confirm a feasible method of comparing different CAR designs within individual patients, potentially offering objective insights that may facilitate the development of optimal CAR-T cell-based immunotherapies. Several recent clinical trials have successfully incorporated a costimulatory domain derived from either CD28 or 4-1BB with the original CD3ζ T cell activating domain to form second-generation chimeric antigen receptors (CARs) that can increase the responsiveness and survival of CAR-engineered T (CAR-T) cells. However, a rigorous assessment of the individual benefits of these costimulatory components relative to the in vivo performance of infused T cells in patients is still lacking. Therefore, we have designed a study that allows us to investigate and compare the impact of different costimulatory signal domains on CAR-T cells in vivo. Patients with B cell leukemia were infused with a mixture of two types of CD19-specific CAR-T cells, individually bearing CD28 (28ζ) and 4-1BB (BBζ) costimulatory signaling domains. We found that such a clinical procedure was feasible and safe. Complete remission (CR) was observed in five of seven enrolled patients, with two patients exhibiting durable CR lasting more than 15 months. The in vivo expansion pattern of 28ζ and BBζ CAR-T cells varied significantly among individual patients. These results confirm a feasible method of comparing different CAR designs within individual patients, potentially offering objective insights that may facilitate the development of optimal CAR-T cell-based immunotherapies." @default.
• W2786284951 created "2018-02-23" @default.
• W2786284951 creator A5008799245 @default.
• W2786284951 creator A5009582503 @default.
• W2786284951 creator A5010422757 @default.
• W2786284951 creator A5028349844 @default.
• W2786284951 creator A5033525770 @default.
• W2786284951 creator A5036123442 @default.
• W2786284951 creator A5044938342 @default.
• W2786284951 creator A5046249498 @default.
• W2786284951 creator A5048379858 @default.
• W2786284951 creator A5049396819 @default.
• W2786284951 creator A5050247259 @default.
• W2786284951 creator A5057872518 @default.
• W2786284951 creator A5066562420 @default.
• W2786284951 creator A5067004399 @default.
• W2786284951 creator A5070361694 @default.
• W2786284951 creator A5085677646 @default.
• W2786284951 creator A5091191484 @default.
• W2786284951 creator A5051580608 @default.
• W2786284951 date "2018-04-01" @default.
• W2786284951 modified "2023-10-10" @default.
• W2786284951 title "In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia" @default.
• W2786284951 cites W1604141497 @default.
• W2786284951 cites W1619537825 @default.
• W2786284951 cites W1940932153 @default.
• W2786284951 cites W1967517831 @default.
• W2786284951 cites W1974431455 @default.
• W2786284951 cites W1977949161 @default.
• W2786284951 cites W2001297737 @default.
• W2786284951 cites W2023068069 @default.
• W2786284951 cites W2028460943 @default.
• W2786284951 cites W2051549641 @default.
• W2786284951 cites W2052971969 @default.
• W2786284951 cites W2057389857 @default.
• W2786284951 cites W2064272625 @default.
• W2786284951 cites W2076991609 @default.
• W2786284951 cites W2082708772 @default.
• W2786284951 cites W2087857484 @default.
• W2786284951 cites W2095434093 @default.
• W2786284951 cites W2099570622 @default.
• W2786284951 cites W2105400883 @default.
• W2786284951 cites W2118796952 @default.
• W2786284951 cites W2124513722 @default.
• W2786284951 cites W2129659050 @default.
• W2786284951 cites W2129702476 @default.
• W2786284951 cites W2130011407 @default.
• W2786284951 cites W2130338247 @default.
• W2786284951 cites W2136100686 @default.
• W2786284951 cites W2145985838 @default.
• W2786284951 cites W2167550136 @default.
• W2786284951 cites W2170513194 @default.
• W2786284951 cites W2207721475 @default.
• W2786284951 cites W2253938658 @default.
• W2786284951 cites W2285239684 @default.
• W2786284951 cites W2302851559 @default.
• W2786284951 cites W2342423058 @default.
• W2786284951 cites W2343067948 @default.
• W2786284951 cites W2509364267 @default.
• W2786284951 cites W2530965063 @default.
• W2786284951 cites W2566677727 @default.
• W2786284951 cites W2587691649 @default.
• W2786284951 cites W3153504824 @default.
• W2786284951 doi "https://doi.org/10.1016/j.ymthe.2018.01.022" @default.
• W2786284951 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6079368" @default.
• W2786284951 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29503204" @default.
• W2786284951 hasPublicationYear "2018" @default.
• W2786284951 type Work @default.
• W2786284951 sameAs 2786284951 @default.
• W2786284951 citedByCount "60" @default.
• W2786284951 countsByYear W27862849512018 @default.
• W2786284951 countsByYear W27862849512019 @default.
• W2786284951 countsByYear W27862849512020 @default.
• W2786284951 countsByYear W27862849512021 @default.
• W2786284951 countsByYear W27862849512022 @default.
• W2786284951 countsByYear W27862849512023 @default.
• W2786284951 crossrefType "journal-article" @default.
• W2786284951 hasAuthorship W2786284951A5008799245 @default.
• W2786284951 hasAuthorship W2786284951A5009582503 @default.
• W2786284951 hasAuthorship W2786284951A5010422757 @default.
• W2786284951 hasAuthorship W2786284951A5028349844 @default.
• W2786284951 hasAuthorship W2786284951A5033525770 @default.
• W2786284951 hasAuthorship W2786284951A5036123442 @default.
• W2786284951 hasAuthorship W2786284951A5044938342 @default.
• W2786284951 hasAuthorship W2786284951A5046249498 @default.
• W2786284951 hasAuthorship W2786284951A5048379858 @default.
• W2786284951 hasAuthorship W2786284951A5049396819 @default.
• W2786284951 hasAuthorship W2786284951A5050247259 @default.
• W2786284951 hasAuthorship W2786284951A5051580608 @default.
• W2786284951 hasAuthorship W2786284951A5057872518 @default.
• W2786284951 hasAuthorship W2786284951A5066562420 @default.
• W2786284951 hasAuthorship W2786284951A5067004399 @default.
• W2786284951 hasAuthorship W2786284951A5070361694 @default.
• W2786284951 hasAuthorship W2786284951A5085677646 @default.
• W2786284951 hasAuthorship W2786284951A5091191484 @default.
• W2786284951 hasBestOaLocation W27862849511 @default.
• W2786284951 hasConcept C147483822 @default.
• W2786284951 hasConcept C148125776 @default.

• next